Trial reportMovement disorders : official journal of the Movement Disorder Society2015
Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study.
Trial report in Movement disorders : official journal of the Movement Disorder Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00950664 (A Double Blind, Randomized, Multi-center, Cross-over Study to Demonstrate the Non-inferiority of Dysport® in Comparison With Botox®, Assuming a Bioequivalence Ratio of 2.5), which is not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Double Blind, Randomized, Multi-center, Cross-over Study to Demonstrate the Non-inferiority of Dysport® in Comparison With Botox®, Assuming a Bioequivalence Ratio of 2.5:1 Units, in the Cervical Dystonia
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Use of AbobotulinumtoxinA in Adults with Cervical Dystonia: A Systematic Literature Review.Toxins · 2020Pooled it
- Guideline
- Trial
- Pilot Single-Blind Trial of AbobotulinumtoxinA in Oromandibular Dystonia.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2018Trial
- The Effectiveness of Botulinum Toxin Injection for Cricopharyngeal Dysfunction-Related Dysphagia in Nasopharyngeal Carcinoma Patients.Dysphagia · 2026Article
- Diffusion Characteristics of LetibotulinumtoxinA, OnabotulinumtoxinA, and AbobotulinumtoxinA and its Impact on Muscle Relaxation: A Randomized Split-Face Clinical Trial.Dermatology and therapy · 2025Article
- Review
- Review
- Conversion to AbobotulinumtoxinA Increases Waning Time and Efficacy for Cervical Dystonia.Movement disorders clinical practice · 2023Article
- Factors Influencing the Surgical Decision in Dystonia Patients Referred for Deep Brain Stimulation.Toxins · 2021Article
- Botulinum Toxin in Movement Disorders: An Update.Toxins · 2021Review
- A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: An international group consensus.Journal of rehabilitation medicine · 2021Article
- Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia.Journal of clinical movement disorders · 2020Article
- Spectrum of practice in the routine management of cervical dystonia with abobotulinumtoxinA: findings from three prospective open-label observational studies.Journal of clinical movement disorders · 2018Article
- Botulinum neurotoxin formulations: overcoming the confusion.Clinical, cosmetic and investigational dermatology · 2018Review
- Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin.Frontiers in neurology · 2017Review
- Review
- Unmet Needs in the Management of Cervical Dystonia.Frontiers in neurology · 2016Article
- A Retrospective, Single-Center Comparative Cost Analysis of OnabotulinumtoxinA and AbobotulinumtoxinA for Cervical Dystonia Treatment.Journal of managed care & specialty pharmacy · 2015Article
- Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal.Functional neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 12 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to compare Dysport (abobotulinumtoxinA, Ipsen Biopharm, Slough, UK) and Botox (onabotulinumtoxinA, Allergan, Irvine, CA, USA) at a 2.5:1 ratio in the treatment of cervical dystonia (CD). A Dysport/Botox ratio of lower than 3:1 was suggested as a more appropriate conversion ratio, considering its higher efficacy and more frequent incidence of adverse effects not only in the treatment of CD but also in other focal movement disorders. A randomized, double-blind, multicenter, non-inferiority, two-period crossover study was done in CD, with a duration of at least 18 months. Patients were randomly assigned to treatment for the first period with Dysport or Botox, and they were followed up for 16 weeks after the injection. After a 4-week washout period, they were switched to the other formulation and then followed up for 16 weeks. The primary outcome was the changes in the Tsui scale between the baseline value and that at 1 month after each injection. A total of 103 patients were enrolled, and 94 completed the study. Mean changes in the Tsui scale between baseline and 4 weeks after each injection tended to favor Botox; however, this was not statistically significant (4.0 ± 3.9 points for the Dysport treatment vs. 4.8 ± 4.1 points for Botox; 95% confidence interval, -0.1-1.7; P = 0.091). The mean change of the Toronto western spasmodic torticollis rating scale score, the proportion of improvement in clinical global impression and patient global impression, and the incidences of adverse events were not significantly different between the two treatments. With regard to safety and efficacy, Dysport was not inferior to Botox in patients with CD at a conversion factor of 2.5:1. [clinicaltrial.gov: NCT00950664]
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.